SPECTRA DX

The Future is Now. Keeping You at the Forefront of Clinical Excellence.

Addiction Labs is the specialist for addiction treatment professionals committed to better outcomes. Substance use treatment providers are facing new pressure to improve outcomes and reduce healthcare costs. Addiction Labs supports its partners through this journey by providing integrative healthcare for all patients.

TO VIEW OUR CLINICAL MENU

Hematology
Chemistry
Hormone Testing
Infectious Disease
Urinalysis

Comprehensive Medical Screening

  • Addiction impacts the whole body
    • All other areas of healthcare address diseases according to
      their entire impact on the patient, shouldn’t the disease of
      addiction be the same?
    • Addiction treatment is often the first line of medical care in
      relevant/recent patient medical history – CATCH IT EARLY.
    • Leaders in addiction treatment are breaking down the silo
      between substance abuse treatment and general health care
      delivery.
co-occuring disorders

Major insurers are promoting high quality behavioral-addiction-medical integrative care as they move toward VBR models.

  • An estimated $38-68 billion can potentially be saved annually through effective integration of medical and behavioral services.
  • These cost savings represent 16%-28% of all spending for MH/SUD services.

Value Based Care

  • Actionable data and quality testing for improved clinical outcomes and reduced healthcare spend
  • Cost effective care
    • Guideline driven reflex and customized testing
    • Reducing operational complexity
    • One patient, one lab order, one result
    • MAT: Right medication and right dose earlier in treatment
  • Build your referral network while enhancing patient care
    • Leaders in addiction treatment are breaking down the silo between substance abuse treatment and general health care delivery
  • Powerful reporting made easy
    • Patient result trends
    • Peer comparisons between physicians and facilities
    • Outlier Reporting

Care Gaps: Diagnostic Testing in Addiction Treatment

  • Menu needs to be more specific & responsive to the market
  • Full diagnostic assessment 48 hrs from intake: 24hr TAT
  • False +/- are detrimental to treatment progress
  • On site research and development team
  • Urine specimen type for all toxicology
  1. www.statnews.com/sponsor/2018/06/07/silent-threat-chronic-hepatitis-c-opioid-epidemic/
    www.ncbi.nlm.nih.gov/pmc/articles/PMC5347641/
    www.cdc.gov/hiv/group/hiv-idu.html
    www.who.int/hiv/topics/idu/en/
    www.cdc.gov/tobacco/data_statistics/sgr/50th-anniversary/index.htm
    www.ncbi.nlm.nih.gov/pmc/articles/
    U.M. Stamer, L.Zhang, F. Stuber Personalized therapy in pain management: where do we stand? Pharmacogenomcis, 11 (2010), pp. 843-864.
    P. Klepstad, T.T. Rakvag, S. Kaasa, M. Holthe, O. Dale, P.C. Borchgrevink, et al. The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand, 48 (2004), pp. 1232-1239.
    B. Lalovic, E. Kharasch, C. Hoffer, L. Risler, L.Y. Liu-Chen, D.D. Shen Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther, 79 (2006), pp. 461-479.
    J. Kirchheiner, H. Schmidt, M. Tzvetkow, JT. Keulen, J. Lotsch, I. Roots, et al. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizer due to CYP2D6 duplication. Pharmacogenomics J, 7 (2007), pp. 257-265.
    S. Rendic, F.J. Di Carlo Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev, 29 (1997), pp. 413-580.
    M. Eichelbaum, M. Ingelman-Sundberg, W.E. Evans Pharmacogenomics and individualized drug therapy. Annu Rev Med, 57 (2006), pp. 119-137.
    Y. Gasche, Y. Daali, M. Fathi, A. Chiappe, S. Cottini, P. Dayer, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med, 351 (2004),pp. 2827-2831.
    G. Koren, J. Cairns, D. Chitayat, A. Gaedigk, S.J. Leeder Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet, 368 (2006), p. 704.
    Winner J, et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psych 2013;3, e242;doi:10.1038/tp.2013.2;published online 19
    March 2013.
    Herbild L, et al. Does Pharmacogenetics Testing for CYP450 2D6 and 2C19 Among Patients with Diagnoses within the Schizophrenic Spectrum Reduce Treatment Cost? Basic & Clin Pharmacol & Toxicol 2013; doi 10.1111/bcpt.12093.
    Chou WH, et al. Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Cost Associated with Severe Mental Illness. J Clin Psychopharmacol 2000; 20(2):246-251.
    Qing Yan (ed.). Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology vol. 1175; doi 10. 1007/978-1-4939-0956-8_15.
    D. Nielsen, E. Nielsen, T. Dasari, C. Spellicy. Pharmacogenetics of Addiction Therapy. Methods in Molecular Biology, volume 1175, pp 589-624.
Menu